BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colon Cancer
- Colorectal Cancer
- Design
- Observational Model: Case-ControlTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objectives: Examine the impact of SIGNATERA™ on adjuvant treatment decisions Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™ Secondary objectives: Molecular residual disease clearance as assessed by SIGNATERA™ Percent of patients undergoing...
Primary Objectives: Examine the impact of SIGNATERA™ on adjuvant treatment decisions Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™ Secondary objectives: Molecular residual disease clearance as assessed by SIGNATERA™ Percent of patients undergoing surgery for oligometastatic recurrence Survival in patients treated with adjuvant versus no adjuvant chemotherapy in patients with SIGNATERA™ negative test results Overall survival Impact of SIGNATERA™ test results on patient quality of life
Tracking Information
- NCT #
- NCT04264702
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Alexey Aleshin, MD, MBA Natera, Inc.
Get Well Soon